These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

665 related articles for article (PubMed ID: 30721720)

  • 41. Comparative toxicity and dosimetric profile of whole-pelvis versus prostate bed-only intensity-modulated radiation therapy after prostatectomy.
    Deville C; Vapiwala N; Hwang WT; Lin H; Ad VB; Tochner Z; Both S
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1389-96. PubMed ID: 21664069
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer: late toxicity.
    Quon H; Cheung PC; Loblaw DA; Morton G; Pang G; Szumacher E; Danjoux C; Choo R; Thomas G; Kiss A; Mamedov A; Deabreu A
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):898-905. PubMed ID: 21237581
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Late Side Effects After Image Guided Intensity Modulated Radiation Therapy Compared to 3D-Conformal Radiation Therapy for Prostate Cancer: Results From 2 Prospective Cohorts.
    Wortel RC; Incrocci L; Pos FJ; van der Heide UA; Lebesque JV; Aluwini S; Witte MG; Heemsbergen WD
    Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):680-9. PubMed ID: 27055398
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Japanese multi-institutional phase II study of moderate hypofractionated intensity-modulated radiotherapy with image-guided technique for prostate cancer.
    Nakamura K; Nihei K; Saito Y; Shikama N; Noda SE; Hara R; Imagumbai T; Mizowaki T; Akiba T; Kunieda E; Someya M; Ohga S; Kawamori J; Kozuka T; Ota Y; Inaba K; Kodaira T; Itoh Y; Funakoshi K; Kagami Y
    Int J Clin Oncol; 2024 Jun; 29(6):847-852. PubMed ID: 38630382
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Favorable 10-year outcomes of image-guided intensity-modulated radiotherapy combined with long-term androgen deprivation for Japanese patients with nonmetastatic prostate cancer.
    Tomita N; Soga N; Ogura Y; Furusawa J; Tanaka H; Koide Y; Tachibana H; Kodira T
    Asia Pac J Clin Oncol; 2019 Feb; 15(1):18-25. PubMed ID: 30411504
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Image-guided radiotherapy for prostate cancer: a prospective trial of concomitant boost using indium-111-capromab pendetide (ProstaScint) imaging.
    Wong WW; Schild SE; Vora SA; Ezzell GA; Nguyen BD; Ram PC; Roarke MC
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e423-9. PubMed ID: 21477947
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term Outcomes of Radiotherapy Regimen of 72 Gy in 30 Fractions for Prostate Cancer.
    Tamari K; Oh RJ; Masai N; Shiomi H; Otani K; Suzuki O; Ogawa K
    Anticancer Res; 2018 Jul; 38(7):4207-4212. PubMed ID: 29970552
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of Image-Guided Intensity-Modulated Radiotherapy and Low-dose Rate Brachytherapy with or without External Beam Radiotherapy in Patients with Localized Prostate Cancer.
    Tsubokura T; Yamazaki H; Masui K; Sasaki N; Shimizu D; Suzuki G; Nakamura S; Yamada K; Okihara K; Shiraishi T; Yoshida K; Nishikawa T; Okabe H
    Sci Rep; 2018 Jul; 8(1):10538. PubMed ID: 30002393
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Risk of late toxicity in men receiving dose-escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial.
    Hoffman KE; Voong KR; Pugh TJ; Skinner H; Levy LB; Takiar V; Choi S; Du W; Frank SJ; Johnson J; Kanke J; Kudchadker RJ; Lee AK; Mahmood U; McGuire SE; Kuban DA
    Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):1074-84. PubMed ID: 24661661
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of hypofractionation and standard fractionation for post-prostatectomy salvage radiotherapy in patients with persistent PSA: single institution experience.
    Murgic J; Jaksic B; Prpic M; Kust D; Bahl A; Budanec M; Prgomet Secan A; Franco P; Kruljac I; Spajic B; Babic N; Kruslin B; Zovak M; Zubizarreta E; Rosenblatt E; Fröbe A
    Radiat Oncol; 2021 May; 16(1):88. PubMed ID: 33980277
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of high-dose (86.4 Gy) IMRT vs combined brachytherapy plus IMRT for intermediate-risk prostate cancer.
    Spratt DE; Zumsteg ZS; Ghadjar P; Kollmeier MA; Pei X; Cohen G; Polkinghorn W; Yamada Y; Zelefsky MJ
    BJU Int; 2014 Sep; 114(3):360-7. PubMed ID: 24447404
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hypofractionated Intensity-modulated Radiotherapy for Intermediate- and High-risk Prostate Cancer: A Retrospective Study.
    Kubo N; Kawamura H; Oike T; Sato H; Iwanaga M; Mizukami T; Adachi A; Matsui H; Ito K; Suzuki K; Nakano T
    In Vivo; 2019; 33(4):1235-1241. PubMed ID: 31280214
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term Outcomes of a Dose-reduction Trial to Decrease Late Gastrointestinal Toxicity in Patients with Prostate Cancer Receiving Soft Tissue-matched Image-guided Intensity-modulated Radiotherapy.
    Sasaki N; Yamazaki H; Shimizu D; Suzuki G; Masui K; Nakamura S; Okabe H; Nishikawa T; Yoshida K
    Anticancer Res; 2018 Jan; 38(1):385-391. PubMed ID: 29277799
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Early outcomes of high-dose-rate brachytherapy combined with ultra-hypofractionated radiation in higher-risk prostate cancer.
    Gorovets D; Hopkins M; Kollmeier M; Moore A; Goel A; Shasha D; Brennan V; McBride S; Cohen G; Damato AL; Zelefsky MJ
    Brachytherapy; 2021; 20(6):1099-1106. PubMed ID: 34588146
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Long-term outcomes of a phase II trial of moderate hypofractionated image-guided intensity modulated radiotherapy (IG-IMRT) for localized prostate cancer.
    Lieng H; Pintilie M; Bayley A; Berlin A; Bristow R; Chung P; Gospodarowicz M; Huang R; Ménard C; Warde P; Catton C
    Radiother Oncol; 2017 Jan; 122(1):93-98. PubMed ID: 27838147
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A comparison of acute and chronic toxicity for men with low-risk prostate cancer treated with intensity-modulated radiation therapy or (125)I permanent implant.
    Eade TN; Horwitz EM; Ruth K; Buyyounouski MK; D'Ambrosio DJ; Feigenberg SJ; Chen DY; Pollack A
    Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):338-45. PubMed ID: 18207665
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Acute toxicity after image-guided intensity modulated radiation therapy compared to 3D conformal radiation therapy in prostate cancer patients.
    Wortel RC; Incrocci L; Pos FJ; Lebesque JV; Witte MG; van der Heide UA; van Herk M; Heemsbergen WD
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(4):737-44. PubMed ID: 25752386
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Toxicity assessment of pelvic intensity-modulated radiotherapy with hypofractionated simultaneous integrated boost to prostate for intermediate- and high-risk prostate cancer.
    McCammon R; Rusthoven KE; Kavanagh B; Newell S; Newman F; Raben D
    Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):413-20. PubMed ID: 19362783
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase 2 trial of guideline-based postoperative image guided intensity modulated radiation therapy for prostate cancer: Toxicity, biochemical, and patient-reported health-related quality-of-life outcomes.
    Berlin A; Cho E; Kong V; Howell KJ; Lao B; Craig T; Bayley A; Chung P; Gospodarowicz M; Warde P; Catton C; Bristow RG; Ménard C
    Pract Radiat Oncol; 2015; 5(5):e473-e482. PubMed ID: 25899220
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Outcomes for prostate glands >60 cc treated with low-dose-rate brachytherapy.
    Pham YD; Kittel JA; Reddy CA; Ciezki JP; Klein EA; Stephans KL; Tendulkar RD
    Brachytherapy; 2016; 15(2):163-8. PubMed ID: 26796717
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.